FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934
                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  FORM 10-KSB/A

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934 for the fiscal year ended DECEMBER 31, 1998.

                                       OR

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 for the transition period from __________________to________________.

                          Commission File Number 0-9860

                        BIOSEARCH MEDICAL PRODUCTS, INC.
          -------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         NEW JERSEY                                          22-2090421
--------------------------------                      ------------------------
 (State or other jurisdiction of                         (I.R.S. Employer
  incorporation or organization)                       Identification Number)

35 INDUSTRIAL PARKWAY, SOMERVILLE, NEW JERSEY                     08876-1276
---------------------------------------------                  ----------------
   (Address of principal executive offices)                    (Zip Code + 4)

Registrant's telephone number, including area code: (908) 722-5000

           Securities registered pursuant to Section 12(b) of the Act:

    Title of each class                   Name of exchange on which registered
    -------------------                   ------------------------------------
           NONE                                          NONE

           Securities registered pursuant to Section 12(g) of the Act:
                         COMMON STOCK, WITHOUT PAR VALUE
                         -------------------------------
                                (Title of class)

     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                [X] YES                    [ ] No

     Indicate by check mark if the disclosure of delinquent filers pursuant to
item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of the registrants knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this form 10-K or any
amendment to this form 10-K. [ ]

     THE AGGREGATE MARKET VALUE ON MARCH 28, 1999 OF VOTING STOCK HELD BY
NON-AFFILIATE OF THE REGISTRANT IS ESTIMATED TO BE $250,000.

     THE NUMBER OF SHARES OUTSTANDING OF THE REGISTRANTS COMMON STOCK, NO PAR
VALUE, AT MARCH 28, 1999 WAS 2,202,878.

     List hereunder the documents, all or portions of which are incorporated by
reference herein, and the Part of the Form 10-K into which the document is
incorporated: Proxy Statement to be filed with respect to the 1998 Annual
Meeting of the Shareholders, Form 8-K and Form 8 filed prior to this 10-K --
Part III.
<PAGE>


THE FOLLOWING EXHIBITS ARE INCORPORATED BY THE RESPECTIVE REFERENCE SYMBOL TO
THE ANNUAL REPORT ON FORM 10-K SB FOR THE FISCAL YEAR ENDED DECEMBER 31, 1993:

10(qqqq)    Product distribution and license agreements between Biosearch
            Medical Products, Inc. and N. V. Verenigde Bedrijven Nutricia, dated
            April 8, 1993.

10(rrrr)    Product distribution and license agreements between Biosearch
            Medical Products, Inc. and C. R. Bard, dated January 1, 1994.

THE FOLLOWING EXHIBITS ARE INCORPORATED BY THE RESPECTIVE REFERENCE SYMBOL TO
THE ANNUAL REPORT ON FORM 10-K SB FOR THE FISCAL YEAR ENDED DECEMBER 31, 1994:

10(ssss)    Asset Purchase Agreement Pee Wee Tube product line between Biosearch
            Medical Products, Inc. and C. R. Bard, dated April 4, 1994.

10(tttt)    Asset Purchase Agreement including product supply patent license
            J-Tube Supply and Escrow Agreements between Biosearch Medical
            Products, Inc. and Sherwood Medical Products (subsidiary American
            Home Products), dated May 19, 1994.

THE FOLLOWING EXHIBITS ARE INCORPORATED BY THE RESPECTIVE REFERENCE SYMBOL TO
THE ANNUAL REPORT ON FORM 10-K SB FOR THE FISCAL YEAR ENDED DECEMBER 31, 1996:

10(uuuu)    Amendment to Supply Agreement with Sherwood Medical passing minimum
            purchase dated March 19, 1996.

THE FOLLOWING EXHIBITS ARE INCORPORATED BY THE RESPECTIVE REFERENCE SYMBOL TO
THE ANNUAL REPORT ON FORM 10-K SB FOR THE FISCAL YEAR ENDED DECEMBER 31, 1997:

10(vvvv)    Contract of sale of between Biosearch and Rebtex for sale of
            Company's building dated November 24, 1997 and terminated in April,
            1998.

THE FOLLOWING EXHIBITS ARE INCORPORATED BY THE RESPECTIVE REFERENCE SYMBOL TO
THE ANNUAL REPORT ON FORM 10-K SB FOR THE FISCAL YEAR ENDED DECEMBER 31,1998:

10(wwww)    Contract of sale between Biosearch and Hydromer for the sale of the
            building dated March, 1998, closed June 12, 1998

10(xxxx)    Three year lease of Company's headquarters from Hydromer on June 12,
            1998, prepaid at $346,500.

10(yyyy)    Standstill Agreement between C.R.Bard and Biosearch dated August 14,
            1998 preventing the Company from offering the urinary catheter
            business to others, extended on October 30, 1998 at a total
            consideration of $200,000.

THE FOLLOWING EXHIBITS ARE INCORPORATED BY THE RESPECTIVE REFERENCE SYMBOL TO
THE ANNUAL REPORT ON FORM 10-K SB FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999:

10(zzzz)    Asset sale between the Company and C.R. Bard dated February 25, 1999
            selling a coating machine and all technology to manufacture
            intermittent urinary catheters for $650,000 ($200,000 already paid).

<PAGE>


22 - Subsidiary of the Company


                                   EXHIBIT 22

SUBSIDIARY OF THE COMPANY

     The following table sets forth certain information as of December 31, 1992
     concerning the subsidiaries of the Company.

                                                                     PERCENTAGE
                                            PLACE OF                  OWNED BY
                                          INCORPORATION              THE COMPANY
                                          -------------              -----------

     Pouch Laboratories, Inc.              New Jersey                   100%

     During August, 1993 a resolution was passed by the Company's Board Of
     Directors to dissolve Pouch Laboratories, Inc. having no reason to maintain
     the existence of this subsidiary. (See note 4, "Discontinued Operations" -
     1993 10-K SB)

25 - Power of Attorney (see "Power of Attorney" in the Annual Report on
     Form 10-K SB)

<PAGE>


                                POWER OF ATTORNEY

     The Company and each person whose signature appears below hereby appoint
Manfred F. Dyck and Robert C. Keller as attorneys-in-fact with full power of
substitution, severally, to execute in the name and on behalf of the registrant
and each such person, individually and in each capacity stated below, one or
more amendments to the annual report; which amendments may make such changes in
the report as the attorney-in-fact acting deems appropriate and to file any such
amendment to the report with the Securities and Exchange Commission.


                                   SIGNATURES

     Pursuant to the requirements of Section 13 or 15 (d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

     Dated: March 30, 1999

                          BIOSEARCH MEDICAL PRODUCTS INC.

                          By: /s/ MANFRED F. DYCK
                                  ----------------------------
                                  Manfred F. Dyck
                                  Chief Executive Officer
                                  Chairman Board of Directors

     Pursuant to the requirements of the Securities and Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

     Dated: March 30, 1999

                          By: /s/ MANFRED F. DYCK
                                  ----------------------------
                                  Manfred F. Dyck
                                  Chief Executive Officer
                                  Chairman Board of Directors


     Dated: March 30, 1999

                          By: /s/ ROBERT C. KELLER
                                  ----------------------------
                                  Robert C. Keller
                                  Chief Accounting Officer and
                                  Treasurer

<PAGE>



                                SIGNATURES (cont)

     Dated: March 30, 1999

                          By: /s/ MARTIN C. DYCK
                                  ----------------------------
                                  Martin C. Dyck
                                  Director


     Dated: March 30, 1999

                          By: /s/ DAVID M. SCHRECK, M.D.
                                  ----------------------------
                                  David M. Schreck, M.D.
                                  Director


     Dated: March 30, 1999

                          By: /s/ KLAUS J.H. MECKELER, M.D.
                                  ----------------------------
                                  Klaus J.H. Meckeler, M.D.
                                  Director


     Dated: March 30, 1999

                          By: /s/ FREDERICK L. PERL, M.D.
                                  ----------------------------
                                  Frederick L. Perl, M.D.
                                  Director